Xi'an Janssen new anti AIDS drug puzeli is listed in China

On July 23, Xi'an Janssen Pharmaceutical Co., Ltd., a subsidiary of Johnson & Johnson Pharmaceutical Co., Ltd., announced that the State Drug Administration has officially approved the use of puzeli ® (darunavicobista tablets) in combination with other antiretroviral drugs to treat adult patients with human immunodeficiency virus (HIV) infection, including: the first treatment of adult patients with antiretroviral drugs, as well as the non delivery of antiretroviral drugs Adult patients who were previously treated with antiretroviral drugs now have mutations related to resistance to darunavir Proselli ® consists of a fixed dose of the HIV protease inhibitor darunavir (800 mg) and the pharmacokinetics synergist corbistar (150 mg) For the treatment of HIV infection, the current general program is more complex, patients often need to take a variety of drugs, low compliance Only one tablet per day is needed for the treatment of HIV infection with puzeli ® in combination with other HIV-1 drugs Clinical data show that the efficacy of proselyl ® is confirmed and it has a high resistance gene barrier, which will greatly improve the drug compliance of patients So far, HIV / AIDS is still one of the most serious challenges in the field of global public health China's achievements in the fight against AIDS are obvious to all, but the challenges still exist According to the report of China Center for Disease Control and prevention, China's reported cases of infection are on the rise In 2017, China newly reported HIV / AIDS cases 134, 512 cases, 3 times more than the number of reported cases in 2006 According to a clinical study to evaluate the safety and efficacy of puzeli ® in the treatment of human immunodeficiency virus type 1 (HIV-1) infection, 1 it has a high gene resistance barrier, which helps to reduce the risk of drug resistance The study showed that in adult patients without mutations in the drug resistance related gene of darunavir, puzeli ® can protect human immune function by reducing the viral load (the content of HIV in the blood) to below the measurable level (< 50 copies / ml), and at the same time increase the number of anti infection cells (CD4 + / T-lymphocyte count) In this study, 313 newly treated and previously treated patients received background treatment containing two effective nucleoside reverse transcriptase inhibitors, while receiving 800 mg (400mg / tablet, 2 tablets) of darunavir once a day combined with 150 mg of corbitatin once a day By week 24 of the study, the overall virological response rate (HIV-1 rnahiv infection / AIDS is an extremely complex disease Asgar rangoonwala, President of Xi'an Janssen Pharmaceutical Co., Ltd., said, "it's nice to see that the State Drug Administration has approved the listing of puzeli ®, and we also take this opportunity to fulfill our important commitment in this field, that is, to introduce innovative anti aids products and provide unremitting efforts and support for China's major public health challenges We look forward to the day when AIDS can be completely cured " HIV is a retrovirus that mainly attacks CD4 + T cells in the immune system With the gradual depletion of CD4 + cells, the human immune system is weakened, and patients are susceptible to opportunistic infection and malignant tumors The goal of HIV infection treatment is to reduce the incidence rate and mortality of HIV related diseases, reduce the incidence rate and mortality of non AIDS related diseases, enable patients to get normal life expectancy and improve their quality of life, inhibit viral replication, reduce viral load to lower detection limits and reduce virus variation; rebuild or maintain immune function; reduce abnormal immune activation; reduce HIV Transmission and prevention of mother to child transmission At present, the main treatment for HIV infection is the combination of antiretroviral (ARV) drugs.